首页 > 最新文献

Breast Journal最新文献

英文 中文
Nipple Areolar Complex (NAC) Neurotization After Nipple-Sparing Mastectomy (NSM) in Implant-Based Breast Reconstruction: A Systematic Review of the Literature 保留乳头乳房切除术(NSM)后乳头乳晕复合体(NAC)神经化:系统的文献回顾
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-06 DOI: 10.1155/tbj/2362697
Thomas J. Sorenson, Carter J. Boyd, Jenn J. Park, Kshipra Hemal, Chris Amro, Nicholas Vernice, Alexis Lakatta, Oriana Cohen, Nolan Karp, Mihye Choi

Background

Nipple-sparing mastectomy (NSM) with implant-based breast reconstruction (IBBR) preserves the nipple-areolar complex (NAC) with superior aesthetic results but results in loss of nipple sensation. Nipple neurotization has emerged as a technique to restore the sensory function, yet outcomes remain variable across studies. This systematic review synthesizes the available evidence on nipple neurotization in IBBR, focusing on sensory recovery, patient satisfaction, and surgical techniques.

Methods

A systematic review was conducted following PRISMA guidelines. PubMed, Ovid EMBASE, and Cochrane Library were searched through April 1, 2025, for studies evaluating nipple neurotization in IBBR. Eligible studies included randomized controlled trials, cohort studies, and case series reporting surgical technique, sensory, and/or patient satisfaction outcomes. Data extraction included study characteristics, surgical techniques, sensory outcomes, and patient-reported satisfaction. Risk of bias was assessed using standardized tools.

Results

Six studies met inclusion criteria, comprising 212 patients and 257 neurotized breasts. Sensory recovery was assessed using monofilament testing and patient-reported outcomes. Studies demonstrated overall improvement of NAC sensory outcomes and high patient satisfaction after neurotization. However, variability in neurotization methods, follow-up duration, and specific measured sensory outcomes limited direct comparisons.

Conclusion

Nipple neurotization in IBBR shows promise in enhancing sensory recovery and patient satisfaction after NSM, but heterogeneity in surgical techniques and outcome measures, as well as poor study designs, limits definitive conclusions. Standardized protocols and randomized studies with long-term patient follow-up are needed to establish best practices and optimize neurotization outcomes.

背景:保留乳头乳房切除术(NSM)与假体乳房重建(IBBR)保留了乳头-乳晕复合体(NAC),具有良好的美学效果,但导致乳头感觉丧失。乳头神经化已成为一种恢复感觉功能的技术,但研究结果仍各不相同。本系统综述综合了IBBR中乳头神经化的现有证据,重点是感觉恢复,患者满意度和手术技术。方法按照PRISMA指南进行系统评价。PubMed, Ovid EMBASE和Cochrane Library检索到2025年4月1日,以评估IBBR中乳头神经化的研究。符合条件的研究包括随机对照试验、队列研究和报告手术技术、感觉和/或患者满意度结果的病例系列。数据提取包括研究特征、手术技术、感觉结果和患者报告的满意度。使用标准化工具评估偏倚风险。结果6项研究符合纳入标准,包括212例患者和257例神经化乳房。使用单丝测试和患者报告的结果评估感觉恢复。研究表明,神经化后NAC感觉预后总体改善,患者满意度高。然而,神经化方法、随访时间和具体测量的感觉结果的可变性限制了直接比较。结论乳头神经化治疗IBBR有望增强NSM后的感觉恢复和患者满意度,但手术技术和结果测量的异质性以及不良的研究设计限制了明确的结论。标准化的方案和随机的长期随访研究需要建立最佳实践和优化神经化的结果。
{"title":"Nipple Areolar Complex (NAC) Neurotization After Nipple-Sparing Mastectomy (NSM) in Implant-Based Breast Reconstruction: A Systematic Review of the Literature","authors":"Thomas J. Sorenson,&nbsp;Carter J. Boyd,&nbsp;Jenn J. Park,&nbsp;Kshipra Hemal,&nbsp;Chris Amro,&nbsp;Nicholas Vernice,&nbsp;Alexis Lakatta,&nbsp;Oriana Cohen,&nbsp;Nolan Karp,&nbsp;Mihye Choi","doi":"10.1155/tbj/2362697","DOIUrl":"https://doi.org/10.1155/tbj/2362697","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nipple-sparing mastectomy (NSM) with implant-based breast reconstruction (IBBR) preserves the nipple-areolar complex (NAC) with superior aesthetic results but results in loss of nipple sensation. Nipple neurotization has emerged as a technique to restore the sensory function, yet outcomes remain variable across studies. This systematic review synthesizes the available evidence on nipple neurotization in IBBR, focusing on sensory recovery, patient satisfaction, and surgical techniques.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review was conducted following PRISMA guidelines. PubMed, Ovid EMBASE, and Cochrane Library were searched through April 1, 2025, for studies evaluating nipple neurotization in IBBR. Eligible studies included randomized controlled trials, cohort studies, and case series reporting surgical technique, sensory, and/or patient satisfaction outcomes. Data extraction included study characteristics, surgical techniques, sensory outcomes, and patient-reported satisfaction. Risk of bias was assessed using standardized tools.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Six studies met inclusion criteria, comprising 212 patients and 257 neurotized breasts. Sensory recovery was assessed using monofilament testing and patient-reported outcomes. Studies demonstrated overall improvement of NAC sensory outcomes and high patient satisfaction after neurotization. However, variability in neurotization methods, follow-up duration, and specific measured sensory outcomes limited direct comparisons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Nipple neurotization in IBBR shows promise in enhancing sensory recovery and patient satisfaction after NSM, but heterogeneity in surgical techniques and outcome measures, as well as poor study designs, limits definitive conclusions. Standardized protocols and randomized studies with long-term patient follow-up are needed to establish best practices and optimize neurotization outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/2362697","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden 程序性死亡配体1 (PDL1)在新辅助三阴性乳腺癌中的表达:与化疗反应和残留癌症负担的关系
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-30 DOI: 10.1155/tbj/8856567
Atif Ali Hashmi, Noreen Wahid, Ghazala Mudassir, Muhammad Irfan, Umair Arshad Malik, Erum Yousuf Khan, Syed Muhammad Abu Bakar, Naveen Faridi
<div> <section> <h3> Background</h3> <p>Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple-negative breast cancer (TNBC), there is a lack of PDL1 expression data in Pakistani breast cancer patients. In our study, PDL1 expression was assessed in TNBC to determine eligibility for PDL1 inhibitors. Our study aimed to evaluate the frequency of PDL1 expression in TNBC. We also examined how PDL1 expression correlates with clinicopathological characteristics and prognostic factors in patients with TNBC. Moreover, the association of neoadjuvant chemotherapy response with PDL1 expression was also evaluated.</p> </section> <section> <h3> Methods</h3> <p>This cross-sectional study was conducted at the Liaquat National Hospital Histopathology Department from January 2022 to June 2023. A total of 128 biopsy-proven cases of TNBCs were administered neoadjuvant chemotherapy before surgery during this period. PDL1 immunohistochemical staining was performed on prechemotherapy needle biopsies. Expression was determined using the combined positive score (CPS). CPS is the number of PDL1-stained cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. Cases with CPS ≥ 10 were considered PDL1-positive.</p> </section> <section> <h3> Results</h3> <p>Complete pathological response (pCR) was observed in 32.8% (<i>n</i> = 42) of cases. PDL1 expression was observed in 18.8% (<i>n</i> = 24) of cases. The majority of cases showed a high residual cancer burden (RCB-III) (<i>n</i> = 53, 41.4%). A significant association was noted between PDL1 expression and neoadjuvant chemotherapy response (<i>p</i> < 0.01). PDL1-positive cases had a higher pCR (<i>n</i> = 16, 66.7%) than PDL1-negative cases (<i>n</i> = 26, 25%). PDL1-positive cases showed a lower frequency of RCB-II-III (RCB-II: 8.3%; RCB-III: 0%) than PDL1-negative cases (RCB-II: 25%; RCB-III: 51%), with a significant <i>p</i> value (<i>p</i> < 0.01).</p> </section> <section> <h3> Conclusion</h3> <p>Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we reco
程序性死亡配体1 (PDL1)在肿瘤中的表达与各种癌症的免疫逃避有关,使这些患者成为PDL1抑制剂的潜在候选者。尽管免疫检查点阻断疗法已被批准用于乳腺癌治疗,特别是三阴性乳腺癌(TNBC),但在巴基斯坦乳腺癌患者中缺乏PDL1表达数据。在我们的研究中,评估了TNBC中PDL1的表达,以确定PDL1抑制剂的资格。我们的研究旨在评估TNBC中PDL1的表达频率。我们还研究了PDL1表达与TNBC患者的临床病理特征和预后因素的关系。此外,还评估了新辅助化疗反应与PDL1表达的关系。方法横断面研究于2022年1月至2023年6月在Liaquat国立医院组织病理学科进行。在此期间,共有128例活检证实的tnbc患者在手术前接受了新辅助化疗。化疗前穿刺活检行PDL1免疫组化染色。采用联合阳性评分(CPS)测定表达。CPS为pdl1染色细胞(肿瘤细胞、淋巴细胞和巨噬细胞)的数量除以活的肿瘤细胞总数乘以100。CPS≥10视为pdl1阳性。结果32.8% (n = 42)的病例病理反应完全。18.8% (n = 24)的病例有PDL1表达。大多数病例显示高残留癌负担(RCB-III) (n = 53, 41.4%)。PDL1表达与新辅助化疗反应有显著相关性(p < 0.01)。pdl1阳性病例的pCR值(n = 16, 66.7%)高于pdl1阴性病例(n = 26, 25%)。pdl1阳性病例RCB-II- iii的频率(RCB-II: 8.3%; RCB-III: 0%)低于pdl1阴性病例(RCB-II: 25%; RCB-III: 51%), p值显著(p < 0.01)。结论总体而言,在我们的研究中,TNBC病例中PDL1表达较低;然而,识别这些病例对于识别那些可以从免疫治疗中受益的病例很重要。我们发现PDL1表达与新辅助化疗反应和RCB显著相关。此外,PDL1阳性与较低的Ki67指数和年龄有关。因此,我们建议在所有TNBC病例中进行常规PDL1检测,以预测新辅助化疗的反应。
{"title":"Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden","authors":"Atif Ali Hashmi,&nbsp;Noreen Wahid,&nbsp;Ghazala Mudassir,&nbsp;Muhammad Irfan,&nbsp;Umair Arshad Malik,&nbsp;Erum Yousuf Khan,&nbsp;Syed Muhammad Abu Bakar,&nbsp;Naveen Faridi","doi":"10.1155/tbj/8856567","DOIUrl":"https://doi.org/10.1155/tbj/8856567","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple-negative breast cancer (TNBC), there is a lack of PDL1 expression data in Pakistani breast cancer patients. In our study, PDL1 expression was assessed in TNBC to determine eligibility for PDL1 inhibitors. Our study aimed to evaluate the frequency of PDL1 expression in TNBC. We also examined how PDL1 expression correlates with clinicopathological characteristics and prognostic factors in patients with TNBC. Moreover, the association of neoadjuvant chemotherapy response with PDL1 expression was also evaluated.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This cross-sectional study was conducted at the Liaquat National Hospital Histopathology Department from January 2022 to June 2023. A total of 128 biopsy-proven cases of TNBCs were administered neoadjuvant chemotherapy before surgery during this period. PDL1 immunohistochemical staining was performed on prechemotherapy needle biopsies. Expression was determined using the combined positive score (CPS). CPS is the number of PDL1-stained cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. Cases with CPS ≥ 10 were considered PDL1-positive.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Complete pathological response (pCR) was observed in 32.8% (&lt;i&gt;n&lt;/i&gt; = 42) of cases. PDL1 expression was observed in 18.8% (&lt;i&gt;n&lt;/i&gt; = 24) of cases. The majority of cases showed a high residual cancer burden (RCB-III) (&lt;i&gt;n&lt;/i&gt; = 53, 41.4%). A significant association was noted between PDL1 expression and neoadjuvant chemotherapy response (&lt;i&gt;p&lt;/i&gt; &lt; 0.01). PDL1-positive cases had a higher pCR (&lt;i&gt;n&lt;/i&gt; = 16, 66.7%) than PDL1-negative cases (&lt;i&gt;n&lt;/i&gt; = 26, 25%). PDL1-positive cases showed a lower frequency of RCB-II-III (RCB-II: 8.3%; RCB-III: 0%) than PDL1-negative cases (RCB-II: 25%; RCB-III: 51%), with a significant &lt;i&gt;p&lt;/i&gt; value (&lt;i&gt;p&lt;/i&gt; &lt; 0.01).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we reco","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/8856567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Era “or Error” of Second Localization Procedures 二次定位程序的时代“或错误”
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-29 DOI: 10.1155/tbj/6391905
Nicole Nelson, Jennifer Den, Roi Weiser, Biai Digbeu, H. Colleen Silva, Angelica S. Robinson, Flavia Poselman, V. Suzanne Klimberg

Background: Clips placed after core needle biopsy are often several millimeters to centimeters from the biopsy cavity. Radiofrequency and radar (R) localization involve a second localization procedure based on the prior clip placement, potentially compounding the distance from the area localized to the original biopsy site. Fluoroscopic intraoperative neoplasm detection (FIND) obviates the need for a second localization by using intraoperative fluoroscopy to localize the original biopsy clip. We hypothesized that intraoperative localization using FIND is feasible and may result in fewer positive margins.

Methods: A retrospective review was performed of patients with nonpalpable malignancy who underwent partial mastectomy from September 2016 to August 2023. Results were compared between patients who underwent R localization vs. FIND. The Pythagorean theorem was used to calculate the distance in space between the biopsy clip and the R localization device. Chi-square was used to calculate the two-tailed p value.

Results: We identified 219 patients: 161 localized with FIND and 55 with R. Three percent (6 out of 161) of the patients with FIND and 12% (7 out of 55) of the patients with R had positive margins (p = 0.01). The average distance between the R device and biopsy clip in patients with positive margins was 19.1 mm, and with negative margins, it was 12.45 mm (p = 0.09).

Conclusions: The positive margin rate with R localization was significantly greater than with FIND. The positive margin rate trended toward increased distance from the localization device to the biopsy clip. Eliminating the second localization decreases painful procedures for the patient and may result in improved tumor-free margins.

背景:芯针活检后放置的夹子通常距离活检腔几毫米到几厘米。射频和雷达(R)定位涉及基于先前夹子放置的第二次定位程序,可能会增加从定位区域到原始活检部位的距离。术中透视肿瘤检测(FIND)通过使用术中透视来定位原始活检夹,从而避免了第二次定位的需要。我们假设术中使用FIND定位是可行的,并且导致较少的阳性切缘。方法:回顾性分析2016年9月至2023年8月行乳房部分切除术的不可触及恶性肿瘤患者。结果比较了进行R定位和FIND的患者。使用勾股定理计算活检夹与R定位装置之间的空间距离。采用卡方法计算双侧p值。结果:我们确定了219例患者:161例局限性FIND和55例R。3%(161例中有6例)的FIND患者和12%(55例中有7例)的R患者边缘呈阳性(p = 0.01)。切缘阳性患者R装置与活检夹的平均距离为19.1 mm,切缘阴性患者R装置与活检夹的平均距离为12.45 mm (p = 0.09)。结论:R定位的阳性切缘率明显高于FIND。阳性切缘率倾向于从定位装置到活检夹的距离增加。消除第二次定位减少了患者的痛苦过程,并可能导致改善的无肿瘤边缘。
{"title":"The Era “or Error” of Second Localization Procedures","authors":"Nicole Nelson,&nbsp;Jennifer Den,&nbsp;Roi Weiser,&nbsp;Biai Digbeu,&nbsp;H. Colleen Silva,&nbsp;Angelica S. Robinson,&nbsp;Flavia Poselman,&nbsp;V. Suzanne Klimberg","doi":"10.1155/tbj/6391905","DOIUrl":"https://doi.org/10.1155/tbj/6391905","url":null,"abstract":"<p><b>Background:</b> Clips placed after core needle biopsy are often several millimeters to centimeters from the biopsy cavity. Radiofrequency and radar (R) localization involve a second localization procedure based on the prior clip placement, potentially compounding the distance from the area localized to the original biopsy site. Fluoroscopic intraoperative neoplasm detection (FIND) obviates the need for a second localization by using intraoperative fluoroscopy to localize the original biopsy clip. We hypothesized that intraoperative localization using FIND is feasible and may result in fewer positive margins.</p><p><b>Methods:</b> A retrospective review was performed of patients with nonpalpable malignancy who underwent partial mastectomy from September 2016 to August 2023. Results were compared between patients who underwent R localization vs. FIND. The Pythagorean theorem was used to calculate the distance in space between the biopsy clip and the R localization device. Chi-square was used to calculate the two-tailed <i>p</i> value.</p><p><b>Results:</b> We identified 219 patients: 161 localized with FIND and 55 with R. Three percent (6 out of 161) of the patients with FIND and 12% (7 out of 55) of the patients with R had positive margins (<i>p</i> = 0.01). The average distance between the R device and biopsy clip in patients with positive margins was 19.1 mm, and with negative margins, it was 12.45 mm (<i>p</i> = 0.09).</p><p><b>Conclusions:</b> The positive margin rate with R localization was significantly greater than with FIND. The positive margin rate trended toward increased distance from the localization device to the biopsy clip. Eliminating the second localization decreases painful procedures for the patient and may result in improved tumor-free margins.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6391905","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life Postdiagnosis: Female Adult Breast Cancer Survivors’ Experience With Physical Activity—A Qualitative Systematic Review 诊断后的生活:女性成年乳腺癌幸存者的体育活动经历-一项定性系统评价
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1155/tbj/6926093
Neeve Brown, Fiona Muirhead

Background: With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast cancer survivors. However, a qualitative perspective is essential to create appropriate adaptations for this population. This study aims to develop a deeper understanding of the experiences of female adult breast cancer survivors with physical activity in their postdiagnosis lifestyle.

Methods: This study followed a qualitative systematic review methodology. In January 2024, six databases (APA PsycInfo, CINAHL Plus, OVID Medline, Scopus, SPORTDiscus and Sports Medicine an Education Index) were searched using aim-specific key terms. Ten studies, comprising a total sample of 200 participants, met the inclusion criteria. Quality appraisal, data extraction and synthesis stages were conducted.

Results: Five main themes emerged during the synthesis stage: (1) Outcomes of Physical Activity Participation, (2) Barriers to Physical Activity, (3) Postdiagnosis Balancing Act, (4) Needs for Future Physical Activity Programs and (5) Next Steps for Breast Cancer Survivors. Additionally, 15 subthemes were identified.

Conclusion: Overall, breast cancer survivors reported positive experiences with physical activity, leading to a desire to maintain an active lifestyle. However, barriers such as treatment side effects, unmet needs for advice from health services and challenges in daily life postdiagnosis were identified. Future research should explore the implementation of specific national guidelines and recommendations for survivors postdiagnosis to overcome these barriers and enhance the quality of survivorship care.

背景:随着乳腺癌存活率的增加,有必要进行更多的研究来了解幸存者的经历。之前的定量研究表明,体育锻炼对乳腺癌幸存者有益。但是,要为这一群体创造适当的适应条件,必须从质量角度出发。本研究旨在更深入地了解成年女性乳腺癌幸存者在诊断后的生活方式中进行体育锻炼的经历。方法:本研究采用定性系统评价方法。在2024年1月,我们使用目标特定的关键词检索了六个数据库(APA PsycInfo、CINAHL Plus、OVID Medline、Scopus、SPORTDiscus和Sports Medicine an Education Index)。10项研究,包括200名参与者的总样本,符合纳入标准。质量评价、数据提取和综合阶段。结果:在综合阶段出现了五个主要主题:(1)体育活动参与的结果;(2)体育活动的障碍;(3)诊断后平衡行为;(4)未来体育活动计划的需求;(5)乳腺癌幸存者的下一步。此外,确定了15个次级主题。结论:总体而言,乳腺癌幸存者报告了积极的体育锻炼经历,导致他们希望保持积极的生活方式。然而,也发现了一些障碍,如治疗副作用、保健服务咨询需求未得到满足以及诊断后日常生活中的挑战。未来的研究应探索实施具体的国家指南和建议,为幸存者诊断后克服这些障碍,提高生存护理的质量。
{"title":"Life Postdiagnosis: Female Adult Breast Cancer Survivors’ Experience With Physical Activity—A Qualitative Systematic Review","authors":"Neeve Brown,&nbsp;Fiona Muirhead","doi":"10.1155/tbj/6926093","DOIUrl":"https://doi.org/10.1155/tbj/6926093","url":null,"abstract":"<p><b>Background:</b> With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast cancer survivors. However, a qualitative perspective is essential to create appropriate adaptations for this population. This study aims to develop a deeper understanding of the experiences of female adult breast cancer survivors with physical activity in their postdiagnosis lifestyle.</p><p><b>Methods:</b> This study followed a qualitative systematic review methodology. In January 2024, six databases (APA PsycInfo, CINAHL Plus, OVID Medline, Scopus, SPORTDiscus and Sports Medicine an Education Index) were searched using aim-specific key terms. Ten studies, comprising a total sample of 200 participants, met the inclusion criteria. Quality appraisal, data extraction and synthesis stages were conducted.</p><p><b>Results:</b> Five main themes emerged during the synthesis stage: (1) Outcomes of Physical Activity Participation, (2) Barriers to Physical Activity, (3) Postdiagnosis Balancing Act, (4) Needs for Future Physical Activity Programs and (5) Next Steps for Breast Cancer Survivors. Additionally, 15 subthemes were identified.</p><p><b>Conclusion:</b> Overall, breast cancer survivors reported positive experiences with physical activity, leading to a desire to maintain an active lifestyle. However, barriers such as treatment side effects, unmet needs for advice from health services and challenges in daily life postdiagnosis were identified. Future research should explore the implementation of specific national guidelines and recommendations for survivors postdiagnosis to overcome these barriers and enhance the quality of survivorship care.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6926093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin Involvement of Idiopathic Granulomatous Mastitis: Sonographic, Clinical, and Histopathological Features 特发性肉芽肿性乳腺炎的皮肤受累:超声、临床和组织病理学特征
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-24 DOI: 10.1155/tbj/7224219
Fatih Işık, Erdal Pala, Fatih Alper, Sevilay Ozmen, Elif Demirci, Hasan Abbasguliyev, Müfide Nuran Akçay

Objectives: Idiopathic granulomatous mastitis (IGM) is a rare benign breast disease in which cutaneous involvement is insufficiently characterized. This study aimed to evaluate the sonographic, clinical, and histopathological features of skin manifestations in IGM.

Methods: We retrospectively analyzed 138 women with biopsy-proven IGM who underwent breast and skin ultrasonography between 2023 and 2024. Clinical cutaneous findings were documented, and 14 patients with visible skin lesions underwent additional punch biopsy for histopathological evaluation. Sonographic and clinical features were stratified according to symptom duration (0–3, 4–6, 7–9, and ≥ 10 weeks).

Results: Cutaneous lesions were identified in 84/138 patients (60.9%). Sonographic findings followed a sequential distribution: fibrous echogenicity loss in early disease (11/14, 78.6%), vacuolar structures at 4–6 weeks (11/19, 57.9%), dermo-subcutaneous blurring at 7–9 weeks (9/34, 26.5%), and advanced features such as fistula formation (11/17, 64.7%) and dermo-subcutaneous disruption (11/17, 64.7%) beyond 10 weeks. Clinical findings paralleled imaging, with erythema and papulopustular lesions predominating early (13/14, 92.9%), erythema nodosum peaking at 4–6 weeks (7/19, 36.8%), and ulceration and fistula formation emerging after ≥ 7 weeks (11/17, 64.7% at ≥ 10 weeks). Histopathological analysis of 14 skin biopsies demonstrated nonspecific inflammatory changes without granuloma formation.

Conclusions: IGM demonstrates sequential sonographic and clinical cutaneous patterns associated with symptom duration. Early erythematous and papulopustular changes progress to ulceration and fistula formation in prolonged disease. Although supportive in suggesting cutaneous involvement, these features are not diagnostic, and histopathological confirmation remains essential. Prospective studies are warranted to further define the clinical and histological course of cutaneous changes in IGM.

目的:特发性肉芽肿性乳腺炎(IGM)是一种罕见的乳腺良性疾病,其累及皮肤的特征不充分。本研究旨在评估IGM皮肤表现的超声、临床和组织病理学特征。方法:我们回顾性分析了2023年至2024年间接受乳腺和皮肤超声检查的138名活检证实的IGM女性。临床皮肤表现被记录下来,14例可见皮肤病变的患者进行了额外的穿刺活检以进行组织病理学评估。根据症状持续时间(0-3周、4-6周、7-9周、≥10周)对超声和临床特征进行分层。结果:138例患者中有84例(60.9%)发现皮肤病变。超声检查结果遵循顺序分布:早期病变纤维回声性丧失(11/14,78.6%),4-6周时空泡结构(11/19,57.9%),7-9周时真皮-皮下模糊(9/34,26.5%),10周后出现晚期特征,如瘘形成(11/17,64.7%)和真皮-皮下破坏(11/17,64.7%)。临床表现与影像学相似,早期以红斑和丘疹病变为主(13/14,92.9%),结节性红斑在4-6周达到高峰(7/19,36.8%),≥7周后出现溃疡和瘘管形成(11/17,≥10周64.7%)。14例皮肤活检的组织病理学分析显示非特异性炎症改变,无肉芽肿形成。结论:IGM显示了与症状持续时间相关的顺序超声和临床皮肤特征。早期的红斑和丘疹性改变进展为溃疡和瘘管形成的长期疾病。虽然支持提示皮肤受累,但这些特征不能诊断,组织病理学证实仍是必要的。有必要进行前瞻性研究,以进一步确定IGM皮肤变化的临床和组织学过程。
{"title":"Skin Involvement of Idiopathic Granulomatous Mastitis: Sonographic, Clinical, and Histopathological Features","authors":"Fatih Işık,&nbsp;Erdal Pala,&nbsp;Fatih Alper,&nbsp;Sevilay Ozmen,&nbsp;Elif Demirci,&nbsp;Hasan Abbasguliyev,&nbsp;Müfide Nuran Akçay","doi":"10.1155/tbj/7224219","DOIUrl":"https://doi.org/10.1155/tbj/7224219","url":null,"abstract":"<p><b>Objectives:</b> Idiopathic granulomatous mastitis (IGM) is a rare benign breast disease in which cutaneous involvement is insufficiently characterized. This study aimed to evaluate the sonographic, clinical, and histopathological features of skin manifestations in IGM.</p><p><b>Methods:</b> We retrospectively analyzed 138 women with biopsy-proven IGM who underwent breast and skin ultrasonography between 2023 and 2024. Clinical cutaneous findings were documented, and 14 patients with visible skin lesions underwent additional punch biopsy for histopathological evaluation. Sonographic and clinical features were stratified according to symptom duration (0–3, 4–6, 7–9, and ≥ 10 weeks).</p><p><b>Results:</b> Cutaneous lesions were identified in 84/138 patients (60.9%). Sonographic findings followed a sequential distribution: fibrous echogenicity loss in early disease (11/14, 78.6%), vacuolar structures at 4–6 weeks (11/19, 57.9%), dermo-subcutaneous blurring at 7–9 weeks (9/34, 26.5%), and advanced features such as fistula formation (11/17, 64.7%) and dermo-subcutaneous disruption (11/17, 64.7%) beyond 10 weeks. Clinical findings paralleled imaging, with erythema and papulopustular lesions predominating early (13/14, 92.9%), erythema nodosum peaking at 4–6 weeks (7/19, 36.8%), and ulceration and fistula formation emerging after ≥ 7 weeks (11/17, 64.7% at ≥ 10 weeks). Histopathological analysis of 14 skin biopsies demonstrated nonspecific inflammatory changes without granuloma formation.</p><p><b>Conclusions:</b> IGM demonstrates sequential sonographic and clinical cutaneous patterns associated with symptom duration. Early erythematous and papulopustular changes progress to ulceration and fistula formation in prolonged disease. Although supportive in suggesting cutaneous involvement, these features are not diagnostic, and histopathological confirmation remains essential. Prospective studies are warranted to further define the clinical and histological course of cutaneous changes in IGM.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7224219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Primary bilateral breast lymphoma in an elder male patient” “老年男性患者原发性双侧乳房淋巴瘤”的勘误表
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-19 DOI: 10.1155/tbj/9821303

Y. Bozkaya, F. Oz Puyan, and B. Bimboga, “Primary bilateral breast lymphoma in an elder male patient,” The Breast Journal 25, no. 5 (2019): 1008-1009, https://doi.org/10.1111/tbj.13394.

In the article titled “Primary bilateral breast lymphoma in an elder male patient,” there was a spelling error in author Busem Binboga’s name in the author list, where Busem Bimboga should have read Busem Binboga. The corrected author list and affiliation list should be as follows:

Yakup Bozkaya1, Fulya Oz Puyan2, Busem Binboga2

1Clinic of Medical Oncology, Edirne State Hospital, Edirne, Turkey

2Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkey

We apologize for this error.

Y. Bozkaya, F. Oz Puyan和B. Bimboga,“老年男性患者的原发性双侧乳房淋巴瘤”,《乳腺杂志》25,第2期。5 (2019): 1008-1009, https://doi.org/10.1111/tbj.13394.In题为“一位老年男性患者的原发性双侧乳房淋巴瘤”的文章,作者名单中作者Busem Binboga的名字出现拼写错误,此处Busem Binboga应该读为Busem Binboga。更正后的作者名单和所属单位名单如下:Yakup bozkay1, Fulya Oz Puyan2, Busem binboga 21土耳其埃迪尔内埃迪尔内国家医院肿瘤医学诊所2土耳其埃迪尔内特拉基亚大学医学院病理学系我们为这个错误道歉。
{"title":"Corrigendum to “Primary bilateral breast lymphoma in an elder male patient”","authors":"","doi":"10.1155/tbj/9821303","DOIUrl":"https://doi.org/10.1155/tbj/9821303","url":null,"abstract":"<p>Y. Bozkaya, F. Oz Puyan, and B. Bimboga, “Primary bilateral breast lymphoma in an elder male patient,” <i>The Breast Journal</i> 25, no. 5 (2019): 1008-1009, https://doi.org/10.1111/tbj.13394.</p><p>In the article titled “Primary bilateral breast lymphoma in an elder male patient,” there was a spelling error in author Busem Binboga’s name in the author list, where Busem Bimboga should have read Busem Binboga. The corrected author list and affiliation list should be as follows:</p><p>Yakup Bozkaya<sup>1</sup>, Fulya Oz Puyan<sup>2</sup>, Busem Binboga<sup>2</sup></p><p><sup>1</sup>Clinic of Medical Oncology, Edirne State Hospital, Edirne, Turkey</p><p><sup>2</sup>Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkey</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9821303","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia” “假性血管瘤间质增生的常规超声和增强超声特征分析”的勘误表
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-19 DOI: 10.1155/tbj/9801706

H. Li, Q. Niu, C. Jia, et al., “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” The Breast Journal 2025 (2025): 6070736, https://doi.org/10.1155/tbj/6070736.

In the article titled “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” there was an error in affiliations 1 and 2 order. The corrected author list and affiliation list should be as follows:

Hui Li1,2, Qinghua Niu1, Chao Jia1, Gaoxiang Fan1, Long Liu1, Gang Li1, Penglin Zou1, Rong Wu1, Lianfang Du1, Jing Wang3, and Qiusheng Shi1

1Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, China

3Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

We apologize for this error.

李宏,牛强,贾超,等,“假性血管瘤间质增生的常规超声和增强超声特征分析”,《乳腺杂志》2025 (2025):6070736,https://doi.org/10.1155/tbj/6070736.In文章标题“假性血管瘤间质增生的常规超声和增强超声特征分析”,在附属关系1和2的顺序上有错误。更正后的作者名单及归属名单应如下:李辉1,2,牛清华1,贾超1,范高翔1,刘龙1,李刚1,邹鹏林1,吴蓉1,杜连芳1,王静3,石秋生11上海交通大学医学院上海总医院超声科2上海复旦大学华山医院超声科3上海总医院病理科,上海交通大学医学院附属医院超声科,上海交通大学附属医院超声科,中国上海上海交通大学医学院,中国上海。我们为这个错误道歉。
{"title":"Corrigendum to “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia”","authors":"","doi":"10.1155/tbj/9801706","DOIUrl":"https://doi.org/10.1155/tbj/9801706","url":null,"abstract":"<p>H. Li, Q. Niu, C. Jia, et al., “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” <i>The Breast Journal</i> 2025 (2025): 6070736, https://doi.org/10.1155/tbj/6070736.</p><p>In the article titled “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” there was an error in affiliations 1 and 2 order. The corrected author list and affiliation list should be as follows:</p><p>Hui Li<sup>1,2</sup>, Qinghua Niu<sup>1</sup>, Chao Jia<sup>1</sup>, Gaoxiang Fan<sup>1</sup>, Long Liu<sup>1</sup>, Gang Li<sup>1</sup>, Penglin Zou<sup>1</sup>, Rong Wu<sup>1</sup>, Lianfang Du<sup>1</sup>, Jing Wang<sup>3</sup>, and Qiusheng Shi<sup>1</sup></p><p><sup>1</sup>Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</p><p><sup>2</sup>Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, China</p><p><sup>3</sup>Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9801706","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators” “在COVID-19时代寻求门诊乳房切除术:障碍和促进因素”的勘误表
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-16 DOI: 10.1155/tbj/9847254

L. J. van Zeelst, R. Derksen, C. H. W. Wijers, et al., “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators,” The Breast Journal 2022 (2022): 1863519, https://doi.org/10.1155/2022/1863519.

In the article titled “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators” there were errors in Figure 1 and Table 1.

In Figure 1 legends, inpatient mastectomy and outpatient mastectomy were attributed to the wrong colour. The corrected Figure 1 is shown below.

In Table 1, values in the polypharmacy rows were incorrect. The corrected Table 1 is shown below.

We apologize for this error.

L. J. van Zeelst, R. Derksen, C. H. W. Wijers等,“The Quest for门诊乳房切除术in COVID-19时代:Barriers and Facilitators”,The Breast Journal 2022 (2022): 1863519, https://doi.org/10.1155/2022/1863519.In文章标题为“The Quest for门诊乳房切除术in COVID-19时代:Barriers and Facilitators”,图1和表1中存在错误。在图1图例中,住院乳房切除术和门诊乳房切除术的颜色都是错误的。更正后的图1如下所示。在表1中,polypharmacy行中的值不正确。更正后的表1如下所示。我们为这个错误道歉。
{"title":"Corrigendum to “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators”","authors":"","doi":"10.1155/tbj/9847254","DOIUrl":"https://doi.org/10.1155/tbj/9847254","url":null,"abstract":"<p>L. J. van Zeelst, R. Derksen, C. H. W. Wijers, et al., “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators,” <i>The Breast Journal</i> 2022 (2022): 1863519, https://doi.org/10.1155/2022/1863519.</p><p>In the article titled “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators” there were errors in Figure 1 and Table 1.</p><p>In Figure 1 legends, inpatient mastectomy and outpatient mastectomy were attributed to the wrong colour. The corrected Figure 1 is shown below.</p><p>In Table 1, values in the polypharmacy rows were incorrect. The corrected Table 1 is shown below.</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9847254","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphological Assessment of Breast Lesions With Type 2 Dynamic Curves Using DWI and T2WI Based on Breast Imaging Reporting and Data System Lexicon Descriptors 基于乳腺影像学报告和数据系统词汇描述符的DWI和T2WI 2型动态曲线乳腺病变形态学评估
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-05 DOI: 10.1155/tbj/9957678
Liying Zhang, Gongsheng Zhu, Kefan Wang, Tongzhen Zhang, Lin Lu, Xin Zhao

Purpose: This study aimed to qualitatively assess the added diagnostic value of diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), using Breast Imaging Reporting and Data System (BI-RADS) lexicon descriptors, in evaluating breast lesions with type 2 dynamic curves.

Materials and Methods: We retrospectively reviewed 181 breast lesions with type 2 dynamic curves in 181 consecutive patients who underwent 3-Tesla (3-T) magnetic resonance imaging (MRI). Trained radiologists assessed the morphological features of the lesions on dynamic contrast-enhanced (DCE) MRI, DWI, and T2WI using BI-RADS lexicon descriptors and measured the apparent diffusion coefficient (ADC). Statistical analysis was performed to compare variables in lesion type groups (mass-like group vs. nonmass-like group). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test, with statistical significance at p < 0.05.

Results: In mass-like lesions, all morphological parameters significantly distinguished benign from malignant lesions on DCE, DWI, and T2WI (all p < 0.05). ADC values also showed significant differences (p < 0.05). The combined approach (DCE + DWI + T2WI) yielded the highest AUC (0.895), significantly outperforming the individual methods (all p < 0.05). In nonmass-like lesions, no parameter significantly predicted malignancy (all p > 0.05).

Conclusion: The addition of DWI and T2WI, interpreted using the BI-RADS lexicon descriptors, enhances the differential diagnosis of breast lesions with type 2 dynamic curves.

目的:本研究旨在利用乳腺成像报告与数据系统(BI-RADS)词汇描述符,定性评估乳腺2型动态曲线病变的弥散加权成像(DWI)和t2加权成像(T2WI)的附加诊断价值。材料和方法:我们回顾性分析了181例连续接受3-特斯拉(3-T)磁共振成像(MRI)的乳房2型动态曲线病变。训练有素的放射科医生使用BI-RADS词汇描述符评估病变在动态对比增强(DCE) MRI、DWI和T2WI上的形态学特征,并测量表观扩散系数(ADC)。对病变类型组(肿块样组与非肿块样组)的变量进行统计分析比较。采用受试者工作特征曲线下面积(AUC)和DeLong检验评价诊断效能,p <; 0.05有统计学意义。结果:在肿块样病变中,DCE、DWI、T2WI各形态参数均能显著区分良恶性病变(p < 0.05)。ADC值也有显著性差异(p < 0.05)。联合方法(DCE + DWI + T2WI)的AUC最高(0.895),显著优于单个方法(均p <; 0.05)。在非肿块样病变中,没有参数显著预测恶性(均p >; 0.05)。结论:使用BI-RADS词汇描述符对DWI和T2WI的增加进行解释,可以增强对2型动态曲线乳腺病变的鉴别诊断。
{"title":"Morphological Assessment of Breast Lesions With Type 2 Dynamic Curves Using DWI and T2WI Based on Breast Imaging Reporting and Data System Lexicon Descriptors","authors":"Liying Zhang,&nbsp;Gongsheng Zhu,&nbsp;Kefan Wang,&nbsp;Tongzhen Zhang,&nbsp;Lin Lu,&nbsp;Xin Zhao","doi":"10.1155/tbj/9957678","DOIUrl":"https://doi.org/10.1155/tbj/9957678","url":null,"abstract":"<p><b>Purpose:</b> This study aimed to qualitatively assess the added diagnostic value of diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), using Breast Imaging Reporting and Data System (BI-RADS) lexicon descriptors, in evaluating breast lesions with type 2 dynamic curves.</p><p><b>Materials and Methods:</b> We retrospectively reviewed 181 breast lesions with type 2 dynamic curves in 181 consecutive patients who underwent 3-Tesla (3-T) magnetic resonance imaging (MRI). Trained radiologists assessed the morphological features of the lesions on dynamic contrast-enhanced (DCE) MRI, DWI, and T2WI using BI-RADS lexicon descriptors and measured the apparent diffusion coefficient (ADC). Statistical analysis was performed to compare variables in lesion type groups (mass-like group vs. nonmass-like group). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test, with statistical significance at <i>p</i> &lt; 0.05.</p><p><b>Results:</b> In mass-like lesions, all morphological parameters significantly distinguished benign from malignant lesions on DCE, DWI, and T2WI (all <i>p</i> &lt; 0.05). ADC values also showed significant differences (<i>p</i> &lt; 0.05). The combined approach (DCE + DWI + T2WI) yielded the highest AUC (0.895), significantly outperforming the individual methods (all <i>p</i> &lt; 0.05). In nonmass-like lesions, no parameter significantly predicted malignancy (all <i>p</i> &gt; 0.05).</p><p><b>Conclusion:</b> The addition of DWI and T2WI, interpreted using the BI-RADS lexicon descriptors, enhances the differential diagnosis of breast lesions with type 2 dynamic curves.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9957678","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii Oncotype DX检测在夏威夷不同乳腺癌人群中的适用性
IF 2 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-01 DOI: 10.1155/tbj/9104103
Kyle Xia, Eileen Chen, Roxana Hu, Ian Pagano, Jami Fukui

Purpose: The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor–positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.

Materials and Methods: We evaluated 879 breast cancer cases diagnosed from January 2018–March 2022 within a major health system in Hawaii, 600 of which received Oncotype DX recurrence scores to provide prognostic and therapy-predictive information based on NCCN guidelines. Linear regression with both univariable (unadjusted) and multivariable (adjusted for all other variables) models was run on the 600 breast cancer cases that received Oncotype DX recurrence scores. The predictor variables were age at diagnosis, race, tumor size, ER/PR status, and histology.

Results: On multivariable analysis, we found statically significant differences in Oncotype DX recurrence scores according to age (60–69 vs. 18–49, p = 0.01), ER/PR status (PR-positive vs. PR-negative, p < 0.0001), histology (other vs. ductal, p = 0.004), and tumor size (2–5 cm vs. 0-1 cm, p = 0.0003). We found no significant differences in Oncotype DX recurrence scores according to race/ethnicity.

Conclusion: Our findings indicate that Oncotype DX recurrence scores are not variable according to race/ethnicity, highlighting the need for further research to understand the known disparities in breast cancer outcomes among different racial/ethnic groups. Our study supports the correlation between Oncotype DX recurrence scores and other factors and aligns with established prognostic trends for these variables in a diverse population. This study supports the applicability for the Oncotype DX test in a diverse breast cancer population of Hawaii.

目的:Oncotype DX检测标准用于早期、激素受体阳性、her2阴性乳腺癌患者,以确定化疗的获益和远处复发的可能性。Oncotype DX复发评分与种族/民族之间的关系仍在研究中。本回顾性研究旨在评估Oncotype DX复发评分、种族/民族和临床病理因素之间的关系,并支持Oncotype DX检测在夏威夷不同乳腺癌人群中的适用性。材料和方法:我们在夏威夷的一个主要卫生系统中评估了2018年1月至2022年3月诊断的879例乳腺癌病例,其中600例接受了Oncotype DX复发评分,以提供基于NCCN指南的预后和治疗预测信息。对600例接受Oncotype DX复发评分的乳腺癌病例进行单变量(未调整)和多变量(对所有其他变量进行调整)模型的线性回归。预测变量为诊断年龄、种族、肿瘤大小、ER/PR状态和组织学。结果:在多变量分析中,我们发现Oncotype DX复发评分在年龄(60-69 vs 18-49, p = 0.01)、ER/PR状态(PR阳性vs PR阴性,p < 0.0001)、组织学(其他vs导管,p = 0.004)和肿瘤大小(2-5 cm vs 0-1 cm, p = 0.0003)方面存在统计学差异。我们发现不同种族/民族的Oncotype DX复发评分无显著差异。结论:我们的研究结果表明,Oncotype DX复发评分不随种族/民族而变化,强调需要进一步研究以了解不同种族/民族之间乳腺癌结局的已知差异。我们的研究支持Oncotype DX复发评分与其他因素之间的相关性,并与不同人群中这些变量的既定预后趋势相一致。本研究支持Oncotype DX检测在夏威夷不同乳腺癌人群中的适用性。
{"title":"Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii","authors":"Kyle Xia,&nbsp;Eileen Chen,&nbsp;Roxana Hu,&nbsp;Ian Pagano,&nbsp;Jami Fukui","doi":"10.1155/tbj/9104103","DOIUrl":"https://doi.org/10.1155/tbj/9104103","url":null,"abstract":"<p><b>Purpose:</b> The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor–positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.</p><p><b>Materials and Methods:</b> We evaluated 879 breast cancer cases diagnosed from January 2018–March 2022 within a major health system in Hawaii, 600 of which received Oncotype DX recurrence scores to provide prognostic and therapy-predictive information based on NCCN guidelines. Linear regression with both univariable (unadjusted) and multivariable (adjusted for all other variables) models was run on the 600 breast cancer cases that received Oncotype DX recurrence scores. The predictor variables were age at diagnosis, race, tumor size, ER/PR status, and histology.</p><p><b>Results:</b> On multivariable analysis, we found statically significant differences in Oncotype DX recurrence scores according to age (60–69 vs. 18–49, <i>p</i> = 0.01), ER/PR status (PR-positive vs. PR-negative, <i>p</i> &lt; 0.0001), histology (other vs. ductal, <i>p</i> = 0.004), and tumor size (2–5 cm vs. 0-1 cm, <i>p</i> = 0.0003). We found no significant differences in Oncotype DX recurrence scores according to race/ethnicity.</p><p><b>Conclusion:</b> Our findings indicate that Oncotype DX recurrence scores are not variable according to race/ethnicity, highlighting the need for further research to understand the known disparities in breast cancer outcomes among different racial/ethnic groups. Our study supports the correlation between Oncotype DX recurrence scores and other factors and aligns with established prognostic trends for these variables in a diverse population. This study supports the applicability for the Oncotype DX test in a diverse breast cancer population of Hawaii.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9104103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1